-
公开(公告)号：WO2013157728A1
公开(公告)日：2013-10-24
申请号：PCT/KR2013/000577
申请日：2013-01-24
Applicant: 대한민국(농촌진흥청장)
IPC: A61K31/4045 , A61K31/404 , A61K31/4035 , A61K36/07
CPC classification number: A61K31/4035 , A61K36/07
Abstract: 본 발명은 아세틸콜린에스터라제 활성 억제제, 치매 예방 또는 치료용 약제학적 조성물 및 뇌신경보호제 및 그 제조방법에 관한 발명이다.
Abstract translation: 本发明涉及乙酰胆碱酯酶抑制剂，用于预防或治疗痴呆的药物组合物，神经保护剂及其制备方法。
-
公开(公告)号：WO2014098307A1
公开(公告)日：2014-06-26
申请号：PCT/KR2013/000579
申请日：2013-01-24
Applicant: 대한민국(농촌진흥청장)
IPC: A61K31/404 , A61K31/4035 , A61P35/00
CPC classification number: A61K31/4035 , A23L2/52 , A23L31/00 , A23L33/125 , A23V2002/00 , A23V2200/308 , A61K36/07
Abstract: 본 발명은 항암제용 약학적 조성물, 건강기능식품 및 이의 제조방법에 관한 것이다.
Abstract translation: 本发明涉及抗癌药物组合物，保健功能食品及其制备方法。
-
3.发明公开백강잠 101Ａ로부터 분리, 정제한 뇌신경성장 촉진물질(4Ｅ, 6Ｅ, 2Ｓ,3Ｒ)-2-Ｎ-도코사노일-4,6-테트라데카스핀가디에닌 有权（4E，6E，2S，3R）-2-N-DOCOSANOY-4,6-TETRADECASPHINGADIENINE从BEAUVERIA BASSIANA 101A分离和纯化
公开(公告)号：KR1020040012398A
公开(公告)日：2004-02-11
申请号：KR1020020045968
申请日：2002-08-03
Applicant: 대한민국(농촌진흥청장) , 성균관대학교산학협력단
IPC: C07C233/05
Abstract: PURPOSE: Provided is new sphingolipid, (4E, 6E, 2S, 3R)-2-N-Docosanoyl-4,6-tetradecasphingadienine which is isolated and purified from Beauveria bassiana 101A and has prevention and treatment effects on degenerative brain diseases. CONSTITUTION: New sphingolipid, (4E, 6E, 2S, 3R)-2-N-Docosanoyl-4,6-tetradecasphingadienine is isolated and purified from Beauveria bassiana 101A and has prevention and treatment effects on degenerative brain diseases. It is characteristically represented by the formula(1). A pharmaceutical preparation for prevention and treatment of brain diseases characteristically contains (4E, 6E, 2S, 3R)-2-N-Docosanoyl-4,6-tetradecasphingadienine as an active ingredient.
Abstract translation: 目的：提供从Beauveria bassiana 101A分离纯化的新型鞘脂（4E，6E，2S，3R）-2-N-二十二烷基-4,6-十四碳环糊精，并对退行性脑病具有预防和治疗作用。 构成：新型鞘脂（4E，6E，2S，3R）-2-N-二十二烷基-4,6-十四碳二烯雌酚从白僵菌101A中分离纯化，对退行性脑病具有预防和治疗作用。 它由式（1）表征。 用于预防和治疗脑疾病的药物制剂特征性地含有（4E，6E，2S，3R）-2-N-二十一烷酰基-4,6-十四碳环糊精作为活性成分。
-
4.发明公开노루궁뎅이 버섯에서 추출된 특정물질을 유효성분으로 포함하는 치매 예방 또는 치료용 약제학적 조성물 및 그 제조방법 有权用于治疗由埃塞克斯提取的特异性物质进行灭绝或治疗的药物组合物及其制备方法
公开(公告)号：KR1020130118131A
公开(公告)日：2013-10-29
申请号：KR1020120041087
申请日：2012-04-19
Applicant: 대한민국(농촌진흥청장)
IPC: A61K31/4045 , A61K31/404 , A61K31/4035 , A61K36/07
CPC classification number: A61K31/4035 , A61K36/07
Abstract: PURPOSE: A pharmaceutical composition for preventing or treating dementia is provided to suppress the activity of acetylcholine esterase, to effectively prevent and treat dementia, and to produce a pharmaceutical composition and a health food. CONSTITUTION: An inhibitor of acetylcholine esterase activation contains a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient. The compounds are derived from Hericium erinacium. A method for manufacturing the inhibitor comprises the steps of: pulverizing Hericium erinacium; adding alcohols to the pulverized Hericium erinacium and concentrating the extract by reduced pressure; preparing a primary fraction from the concentrated extract using an organic solvent; preparing a secondary fraction from the primary fraction through chromatography; and isolating and purifying the compound of chemical formula 1.
Abstract translation: 目的：提供用于预防或治疗痴呆的药物组合物，以抑制乙酰胆碱酯酶的活性，有效预防和治疗痴呆，以及制备药物组合物和保健食品。 构成：乙酰胆碱酯酶活化抑制剂含有化学式1的化合物或其药学上可接受的盐作为活性成分。 该化合物衍生自赫氏酵母（Hericium erinacium）。 制备抑制剂的方法包括以下步骤：粉碎赫氏酵母; 向粉碎的Hericium erinacium中加入醇，并通过减压浓缩提取物; 使用有机溶剂从浓缩提取物中制备一级馏分; 通过色谱从一级馏分制备二级馏分; 并分离和纯化化学式1的化合物。
-
公开(公告)号：KR100466522B1
公开(公告)日：2005-01-15
申请号：KR1020020045969
申请日：2002-08-03
Applicant: 대한민국(농촌진흥청장) , 학교법인 성균관대학
IPC: C07D209/36
Abstract: PURPOSE: Provided are an extract of Paecilomyces sp. J300 having antitumor activity and a pharmaceutical composition containing the same. The extract contains novel antitumor matters, and is thus useful for an antitumor drug composition. CONSTITUTION: A extract of Paecilomyces sp. J300 having antitumor activity contains, as antitumor matters, 5,3-dihydroxy-1-N-methyl-indoline-2-carbonylamino-alanyl-hydoxyisoleucinyl-glycine represented by the formula(1) or its derivatives. An antitumor drug composition contains one of 5,3-dihydroxy-1-N-methyl-indoline-2-carbonylamino-alanyl-hydoxyisoleucinyl-glycine or its derivatives including 5 alpha, 6 alpha-epoxy-(22E,24R)-ergosta-8(14), 22-diene-3 beta, 7 alpha-diol of the formula(2), 5 alpha, 6 alpha-epoxy-(22E, 24R)-ergosta-8, 22-diene-3 beta, 7 alpha-diol of the formula(3), ergosta-4, 6, 8(14), 22-tetraene-3-one of the formula(4) and 3 beta, 5 alpha-dihydroxy-6 beta-methoxyergosta-7, 22-diene of the formula(5).
Abstract translation: 用途：提供了拟青霉菌提取物。 具有抗肿瘤活性的J300及含有其的药物组合物。 提取物含有新的抗肿瘤物质，因此可用于抗肿瘤药物组合物。 组成：拟青霉菌提取物。 具有抗肿瘤活性的J300含有由式（1）表示的5,3-二羟基-1-N-甲基 - 二氢吲哚-2-羰基氨基 - 丙氨酰 - 羟基异黄嘌呤基甘氨酸或其衍生物作为抗肿瘤物质。 抗肿瘤药物组合物含有5,3-二羟基-1-N-甲基 - 二氢吲哚-2-羰基氨基 - 丙氨酰 - 羟基异黄嘌呤基甘氨酸或其衍生物，包括5α，6α-环氧 - （22E，24R） - 肉豆蔻酰 - 8（14），22-二烯-3β，式（2）的7α-二醇，5α，6α-环氧 - （22E，24R）-ergosta-8,22-二烯-3β，7α （3）的二醇，麦角甾-4,6,8（14），22-四烯-3-酮和3β，5α-二羟基-6β-甲氧麦角甾-7,22 （5）的二烯。
-
Patent Agency Ranking
公开(公告)号：KR1020040012399A
公开(公告)日：2004-02-11
申请号：KR1020020045969
申请日：2002-08-03
Applicant: 대한민국(농촌진흥청장) , 학교법인 성균관대학
IPC: C07D209/36
Abstract: PURPOSE: Provided are an extract of Paecilomyces sp. J300 having antitumor activity and a pharmaceutical composition containing the same. The extract contains novel antitumor matters, and is thus useful for an antitumor drug composition. CONSTITUTION: A extract of Paecilomyces sp. J300 having antitumor activity contains, as antitumor matters, 5,3-dihydroxy-1-N-methyl-indoline-2-carbonylamino-alanyl-hydoxyisoleucinyl-glycine represented by the formula(1) or its derivatives. An antitumor drug composition contains one of 5,3-dihydroxy-1-N-methyl-indoline-2-carbonylamino-alanyl-hydoxyisoleucinyl-glycine or its derivatives including 5 alpha, 6 alpha-epoxy-(22E,24R)-ergosta-8(14), 22-diene-3 beta, 7 alpha-diol of the formula(2), 5 alpha, 6 alpha-epoxy-(22E, 24R)-ergosta-8, 22-diene-3 beta, 7 alpha-diol of the formula(3), ergosta-4, 6, 8(14), 22-tetraene-3-one of the formula(4) and 3 beta, 5 alpha-dihydroxy-6 beta-methoxyergosta-7, 22-diene of the formula(5).
Abstract translation: 目的：提供拟青霉菌属 J300具有抗肿瘤活性和含有其的药物组合物。 提取物含有新的抗肿瘤物质，因此可用于抗肿瘤药物组合物。 构成：拟青霉菌提取物 具有抗肿瘤活性的J300含有作为抗肿瘤物质的由式（1）表示的5,3-二羟基-1-N-甲基 - 二氢吲哚-2-羰基氨基 - 丙氨酰 - 羟基异丁烯基 - 甘氨酸或其衍生物。 一种抗肿瘤药物组合物包含5,3-二羟基-1-N-甲基 - 二氢吲哚-2-羰基氨基 - 丙氨酰 - 羟基异亮氨酰基甘氨酸或其衍生物之一，包括5α，6α-环氧 - （22E，24R） 8（14），22-二烯-3β，7α-二醇，5α，6α-环氧 - （22E，24R） - 麦角甾-8,22-二烯-3β，7α 式（3）的二醇，式（4）的麦角胺-4,6,8（14），22-四烯-3-酮和3β，5α-二羟基-6β-甲氧麦角甾-7,22 - 二烯（式（5））。
-
7.发明公开
公开(公告)号：KR1020040012396A
公开(公告)日：2004-02-11
申请号：KR1020020045966
申请日：2002-08-03
Applicant: 대한민국(농촌진흥청장) , 이강노
IPC: C07C233/16
Abstract: PURPOSE: Provided is a beauveria bassiana 101A extract containing an active compound which has excellent activity in nerve cell outgrowth without cytotoxicity. The extract and active compound separated therefrom can reduce atrophy and damages caused by degenerative cerebral diseases including Parkinson's disease and stroke. CONSTITUTION: The active compound from beauveria bassiana extract is represented by formula 1, wherein R is C17 or C19 of alkyl group. The pharmaceutical composition using the active compound from beauveria bassiana extract for treatment or prophylaxis of cerebral diseases comprises one or more selected from a group consisting of 1,7-dimethyl-xanthine, uracil, urea, betain, and tyrosine, as an active compound.
Abstract translation: 目的：本发明提供一种含有活性化合物的白僵菌101A提取物，其在没有细胞毒性的神经细胞生长中具有优异的活性。 从其分离的提取物和活性化合物可以减少由退行性脑疾病（包括帕金森病和中风）引起的萎缩和损伤。 构成：来自白僵菌提取物的活性化合物由式1表示，其中R为烷基的C17或C19。 使用白僵菌提取物的活性化合物用于治疗或预防脑疾病的药物组合物包含选自1-7-二甲基 - 黄嘌呤，尿嘧啶，尿素，甜菜碱和酪氨酸作为活性化合物的一种或多种。
-
公开(公告)号：KR101376246B1
公开(公告)日：2014-03-26
申请号：KR1020120148897
申请日：2012-12-18
Applicant: 대한민국(농촌진흥청장)
IPC: A61K31/404 , A61K31/4035 , A61P35/00
CPC classification number: A61K31/4035 , A23L2/52 , A23L31/00 , A23L33/125 , A23V2002/00 , A23V2200/308 , A61K36/07
Abstract: The present invention relates to a compound represented as chemical formula 1 or an anticancer pharmaceutical composition or food supply containing a pharmaceutically acceptable salt thereof as an active ingredient, and a manufacturing method of the same. (However, X is C=O, or an alkyl group of C_1.)
Abstract translation: 本发明涉及化学式1表示的化合物或其药物可接受的盐作为活性成分的抗癌药物组合物或食品供给体及其制造方法。 （但是，X为C = O或C 1-1的烷基）
-
9.发明授权
公开(公告)号：KR101349113B1
公开(公告)日：2014-01-20
申请号：KR1020120041087
申请日：2012-04-19
Applicant: 대한민국(농촌진흥청장)
IPC: A61K31/4045 , A61K31/404 , A61K31/4035 , A61K36/07
CPC classification number: A61K31/4035 , A61K36/07
Abstract: 본 발명은 하기 화학식 1의 화합물 또는 약제학적으로 허용 가능한 그의 염을 유효성분으로 포함하는 아세틸콜린에스터라제 활성 억제제, 치매 예방 또는 치료용 약제학적 조성물 및 뇌신경보호제 및 그 제조방법에 관한 발명이다. 본 발명에 따른 아세틸콜린에스터라제 활성 억제제, 치매 예방 또는 치료용 약제학적 조성물 및 뇌신경보호제는 치매를 일으키는 원인 중 하나인 아세틸콜린의 활성화를 억제하여 치매를 효과적으로 예방 치료하며, 뇌졸중이나 뇌경색 등으로부터 뇌신경을 효과적으로 보호하는 물질 및 그 제조방법에 관한 발명이다.
[화학식 1]
(단, 상기 X는 , 또는 C1의 알킬기 일 수 있다.)-
10.发明授权백강잠 101Ａ로부터 분리, 정제한 뇌신경성장 촉진물질(4Ｅ, 6Ｅ, 2Ｓ,3Ｒ)-2-Ｎ-도코사노일-4,6-테트라데카스핀가디에닌 有权具有增强神经突生长的白僵菌101A的新型鞘脂，4E，6E，2S，3R-2-N-二十二烷基-4,6-十四碳环己二烯
公开(公告)号：KR100487113B1
公开(公告)日：2005-05-03
申请号：KR1020020045968
申请日：2002-08-03
Applicant: 대한민국(농촌진흥청장) , 성균관대학교산학협력단
IPC: C07C233/05
Abstract: 본 발명은 신경세포 성장 및 분화와 관련된 퇴행성 뇌질환을 치료 및 예방하기 위하여 백강잠 101A(
Beauveria bassiana 101A)의 추출물로부터 분리, 정제한 뇌신경활성 물질인 (4E, 6E, 2S, 3R)-2-N-도코사노일-4,6-테트라데카스핀가디에닌이 퇴행성 뇌질환의 예방 및 치료제로 개발될 수 있도록 하는데 그 목적이 있다.
본 발명에서는 백강잠
101A의 추출물과 이의 활성성분에 대하여 퇴행성 뇌질환에 중요하게 관여하는 신경세포 축색돌기 성장촉진 및 신경영양인자 단백질 증강효과를 PC 12 세포를 이용하여 검색한 결과 증강 및 신경세포 성장 촉진에 탁월한 작용을 가지면서 세포독성은 없는 백강잠
101A로부터 분리한 신규화합물인 (4E, 6E, 2S, 3R)-2-N-도코사노일-4,6-테트라데카스핀가디에닌을 제공함으로써 알쯔하이머, 파킨슨 및 중풍과 같은 퇴행성 뇌질환에 의하여 유발되는 신경세포 위축 및 손상을 경감시켰으며, 아울러 국민건강 증진과 양잠농가의 새로운 소득원으로의 역할이 기대된다.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.017 seconds)
